SMO and melanoma: In the ICI cohort (n = 1,347), 38 patients were carrying SMO mutations, including 9 melanomas, 13 NSCLCs, 1 head and neck cancer cell carcinoma, 3 bladder cancers, 8 colorectal cancers, 2 esophagogastric cancers, and 2 cancers of unknown primary origin, which comprised 2.8% of the population in the pan-cancer cohort.